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Heme oxygenase-1 is dispensable 
for the anti-inflammatory activity 
of intravenous immunoglobulin
Caroline Galeotti1,2,3,4, Pushpa Hegde1,3, Mrinmoy Das1,2,3, Emmanuel Stephen-Victor1,2,3, 
 Fernando Canale1,3, Marcos Muñoz1,3, Varun K. Sharma1,3, Jordan D. Dimitrov1,2,3,5, 
Srini V. Kaveri1,2,3,5,6 & Jagadeesh Bayry1,2,3,5,6
Intravenous immunoglobulin G (IVIG) is used in the therapy of various autoimmune and inflammatory 
conditions. The mechanisms by which IVIG exerts anti-inflammatory effects are not completely 
understood. IVIG interacts with numerous components of the immune system including dendritic cells, 
macrophages, T and B cells and modulate their functions. Recent studies have reported that heme 
oxygenase-1 (HO-1) pathway plays an important role in the regulation of inflammatory response in 
several pathologies. Several therapeutic agents exert anti-inflammatory effects via induction of HO-1. 
Therefore, we aimed at exploring if anti-inflammatory effects of IVIG are mediated via HO-1 pathway. 
Confirming the previous reports, we report that IVIG exerts anti-inflammatory effects on innate 
cells as shown by the inhibitory effects on IL-6 and nitric oxide production and confers protection in 
experimental autoimmune encephalomyelitis (EAE) model. However, these effects were not associated 
with an induction of HO-1 either in innate cells such as monocytes, dendritic cells and macrophages or 
in the kidneys and liver of IVIG-treated EAE mice. Also, inhibition of endogenous HO-1 did not modify 
anti-inflammatory effects of IVIG. These results thus indicate that IVIG exerts anti-inflammatory effects 
independent of HO-1 pathway.
Initially used as replacement therapy in immune deficiencies, IVIG is also widely used for the treatment of a 
number of autoimmune and systemic inflammatory diseases1–5. Despite its therapeutic use for more than three 
decades, the precise mechanism by which IVIG exerts its beneficial effect is not fully understood. Exploration of 
mechanisms of IVIG is useful to define the dosage, to identify an appropriate window and duration of treatment, 
and to delineate biomarkers of therapeutic response. IVIG interacts with numerous components of the immune 
system including dendritic cells (DCs), macrophages, T and B cells and modulate their functions6–21. These mech-
anisms of IVIG also reflect the functions of circulating IgG in the maintenance of immune homeostasis.
Recent studies in various experimental models such as sepsis, cardiovascular pathologies, experimental auto-
immune encephalomyelitis (EAE) and transplantation, and infection models such as Mycobacterium tuberculosis 
have highlighted the biological significance of heme oxygenase-1 (HO-1) enzymatic pathway and the reactive 
products of this pathway in regulating the inflammation and in the adaptation of the pathogens to the host 
microenvironment22–28. HO-1 catalyzes the degradation of heme, resulting in the liberation of equimolar amounts 
of iron, carbon monoxide (CO) and biliverdin. Biliverdin is subsequently converted to bilirubin by biliverdin 
reductase. Congenital defects in HO-1 expression in mice and human are associated with systemic inflamma-
tion29. HO-1 inhibits ovalbumin-induced airway inflammation by enhancing the biological activity of regulatory 
T cells (Tregs) in an IL-10-dependent manner30. Nevertheless, development, maintenance and the functions of 
Tregs under physiological conditions are not dependent on the activity of HO-131.
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CO and biliverdin have potent anti-inflammatory, anti-proliferative, anti-apoptotic, and antioxidant 
activities and exert their effects on many cell types, including cells of the immune system32. CO suppresses 
the pro-inflammatory response and promotes the anti-inflammatory programs of macrophages, DCs and 
monocytes33,34. Thus, either overexpression of HO-1 in innate cells or exposure to CO leads to inhibition of 
pro-inflammatory cytokines and enhancement of IL-10. CO also inhibits the lipopolysaccharide (LPS)-mediated 
maturation of DCs35,36.
Thus, in view of the common anti-inflammatory role exerted by both HO-1 and IVIG, we investigated if 
mechanisms of action of IVIG both in vitro and in vivo implicate HO-1 pathway.
Results
Anti-inflammatory effects of IVIG on human monocytes are not associated with induction of 
HO-1. It is known that IVIG exerts anti-inflammatory effects on innate cells such as monocytes, DCs and 
macrophages leading to suppression of inflammatory cytokines8,37–39. By analysing the production of IL-6, we 
first confirmed the anti-inflammatory action of IVIG. Unstimulated monocytes produced insignificant amount 
of IL-6. However, upon stimulation with LPS, a TLR4-agonist, monocytes produced large amounts of IL-6. 
Importantly, IVIG significantly reduced the production of IL-6, thus validating the anti-inflammatory effects of 
IVIG (Fig. 1a). The inhibition however was not dependant on the dose of IVIG.
We then examined the effect of IVIG on the expression of HO-1. Untreated monocytes expressed marginal 
amount of HO-1 and was not modified by IVIG. Even under inflammatory conditions, IVIG failed to induce the 
expression of HO-1 (Fig. 1b) in all tested concentrations. The lack of expression of HO-1 in IVIG-treated mono-
cytes was not due to technical errors or non-functioning of HO-1-detecting antibodies as treatment of monocytes 
with cobalt protoporphyrin IX (CoPP), an inductor of HO-1, strongly induced HO-1. These results thus suggest 
that anti-inflammatory effects of IVIG on monocytes are independent of HO-1 pathway.
Figure 1. Anti-inflammatory effects of IVIG on human monocytes are not associated with induction of 
HO-1. (a) IVIG suppresses LPS-induced IL-6 production in human monocytes. Human peripheral blood 
monocytes were cultured in RPMI-1640 medium with 10% fetal calf serum either alone (cells alone) 
or with IVIG (5 and 10 mg/ml) for 24 hours. In some conditions, after 24 hours of culture, monocytes were 
exposed to LPS for additional 24 hours. IL-6 in the culture supernatants was measured by ELISA (n = 4). 
*p < 0.05, One-way ANOVA (b) Expression of HO-1 in human monocytes treated with IVIG (5, 10 or 15 mg/
ml) alone or with LPS during last 24 hours of culture. CoPP was used as a positive control to induce HO-1. 
Images have been cropped for presentation and full-size blots are presented in Supplementary Figure S2.
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Inability of IVIG to induce HO-1 in dendritic cells and macrophages. We investigated the effect 
of IVIG on the expression of HO-1 in other innate cells. Consistent with the results obtained with monocytes, 
IVIG did not induce HO-1 both in monocyte-derived human DCs as well as RAW264.7 macrophage cell line 
(Fig. 2a,b). CoPP, the positive control, induced HO-1 in both the cell types. These results thus indicate that inabil-
ity of IVIG to induce HO-1 is not restricted to particular innate cell.
Inhibition of endogenous HO-1 is not coupled with reduced functioning of IVIG. As innate 
cells express basal level of HO-1 (Fig. 1b, 2b), we wondered whether inhibition of this endogenous HO-1 is 
associated with reduced anti-inflammatory action of IVIG. Peritoneal macrophages from C57BL/6J mice and 
RAW264.7 cells were treated with IVIG for 24 hours and followed by stimulation with LPS. The activation 
of macrophages by LPS leads to oxidation of L-arginine via nitric oxide synthase and produce nitric oxide 
(NO). As shown in Fig. 3a,b, IVIG significantly inhibited LPS-induced NO production. However, treatment 
of cells with tin-mesoporphyrin (SnMP) to suppress enzyme activity of the endogenous HO-1 did not inhibit 
anti-inflammatory effects of IVIG on NO production (Fig. 3a,b).
The protective effect of IVIG in experimental autoimmune encephalomyelitis is independent of 
induction of HO-1 in vivo. In order to validate the non-involvement of HO-1 pathway in IVIG-mediated 
anti-inflammatory effects in vivo, we resorted to EAE model. EAE was induced in C57BL/6J mice using MOG35–55. 
Confirming the previous reports, treatment of mice with IVIG significantly delayed the onset of EAE and the 
severity of the disease (Fig. 4a)40–42. However, consistent with in vitro results, this protection was not associated 
with an induction of HO-1 irrespective of the organs examined (liver and kidney) (Fig. 4b). Western blot analysis 
of lungs and spleen also showed same results. Naive mice injected with CoPP (20 mg/kg) were used as positive 
control for the expression of HO-1. In fact, expression of HO-1 was confirmed in the liver and kidneys of these 
mice 24 hours following CoPP injection (Fig. 4b).
Discussion
It was suggested that HO-1 functions as a “therapeutic funnel”32. Several reports in experimental models have 
recently demonstrated that HO-1 pathway and its products could be used for the prevention or treatment of 
immune-mediated disorders. These protective effects are mediated by multiple functions of HO-1 that include 
immunosuppression, anti-inflammatory, anti-apoptosis and anti-oxidant effects. The anti-inflammatory mech-
anisms of HO-1 are mainly via modulation of activation of immune cells including antigen presenting cells and 
lymphocytes32. In fact, IVIG has been demonstrated to modulate the functions of both innate cells and T cells. 
Thus, IVIG was reported to suppress the activation of DCs, macrophages and monocytes and secretion of inflam-
matory cytokines while enhancing anti-inflammatory mediators like IL-10 and IL-1ra. In addition, IVIG also 
inhibits APC-mediated effector T cell activation, proliferation. Recent reports further demonstrate that IVIG 
inhibits Th1 and Th17 subsets, which are pathogenic in various autoimmune and inflammatory diseases, and 
Figure 2. IVIG lacks the capacity to induce HO-1 in dendritic cells and macrophages. (a) Human peripheral 
blood monocyte-derived DCs or (b) RAW264.7 macrophages were cultured in the medium alone or with IVIG 
(5 and 10 mg/ml) for 24 hours. Expression of HO-1 was detected by western blot. CoPP was used as a positive 
control to induce HO-1. Images have been cropped for presentation.
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reciprocally expands Tregs40–48. Importantly, HO-1 appears to be required for the action of several therapeutic 
molecules. For example, rapamycin appears not to exert its anti-proliferative effects on smooth muscle cells unless 
HO-1 is present49. All these different lines of evidence underscore the importance of dissection of HO-1 pathway 
in the anti-inflammatory effects of IVIG.
Previous reports have shown that innate cells express HO-1 in steady state and inhibit toll-like 
receptor-mediated (such as LPS) activation and secretion of pro-inflammatory cytokines35,36,50. Although, the 
expression of HO-1 in monocytes, DC and RAW264.7 was not prominent, we could detect basal expression of 
protein by western blot. However, IVIG did not modulate the basal expression of HO-1. Thus, suppression of 
LPS-mediated IL-6 and NO production by IVIG were independent of HO-1 pathway. It could be argued that 
IVIG-mediated suppression of IL-6 and NO might be due to passive neutralization of LPS by antibodies as we 
pre-treated the innate cells with IVIG before stimulation with LPS. However, as analyzed by the expression of 
CD80 and CD86, IVIG-mediated anti-inflammatory effects was well-preserved in the monocytes even if cells 
were stimulated with LPS followed by treatment with IVIG (Supplementary Fig. S1), thus ruling out passive 
neutralization of LPS as a mechanism of anti-inflammatory effect of IVIG. As activation stimuli such as LPS were 
reported to inhibit the expression of HO-135, we opted for examining if IVIG-preconditioning results in HO-1 
Figure 3. Inhibition of endogenous HO-1 is not associated with loss of anti-inflammatory action of 
IVIG. (a) Peritoneal macrophages from C57Bl/6J mice (n = 3) or (b) RAW264.7 macrophages (n = 3) were 
treated with IVIG (10 mg/ml) for 24 hours. They were then exposed to either LPS alone or LPS and SnMP for 
additional 24 hours. Production of NO was evaluated by Griess method. ***p < 0.001, One-way ANOVA and ns, 
not significant.
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expression in innate cells, which in turn inhibits LPS-mediated activation of cells. Our data however clearly 
demonstrates that IVIG or otherwise, normal circulating antibodies lack the capacity to induce HO-1 and even 
upon inhibition of endogenous HO-1, IVIG-mediated anti-inflammatory effects were not altered.
Tregs play an important role in the prevention of autoimmune and inflammatory responses51. Initial reports 
have indicated that HO-1 in Tregs is critical for their immune suppression functions52. However, subsequent 
reports have contradicted this data and showed that HO-1 expression in Tregs is not key for immunoregulatory 
functions of these cells both in human and mice31,53. As stimuli from DCs are crucial in Treg expansion, subse-
quent report showed that HO-1 expression in DCs mediated suppressive functions of Tregs54. Despite induction 
of DC-mediated Treg expansion by IVIG as reported recently by us and others, we could not observe induction of 
HO-1 in DCs by IVIG suggesting that IVIG targets different pathways for the expansion of Tregs. In fact, several 
lines of evidence suggest that IVIG could expand Tregs via numerous mechanisms, which might act either inde-
pendent or inter-linked 18,19,40,42,48. The modulation of DC functions upon recognition of IVIG via DC-SIGN or 
DICER constitutes a major event40,48. This interaction leads to expression of COX-2-dependent PGE2 production 
in DCs, which in turn expands Tregs. The role of PGE2 in IVIG-mediated Treg expansion was documented both 
in vivo in animal models and in autoimmune patients treated with IVIG40,45.
Experimental models have shown that HO-1 pathway inhibits pathogenic T cell responses. EAE has been used 
as an experimental model for multiple sclerosis and that induction of HO-1 pathway suppress neuro-inflammation 
in EAE23. Induction of HO-1 also suppressed IFN-γ and TNF-α responses of CNS-infiltrating T cells. Suppression 
of Th1 responses by HO-1 was also reported in type 1 diabetes model in NOD mice25. Although modulation of 
Th17 responses by HO-1 in EAE was not analyzed in the previous report, it is likely that HO-1 suppresses Th17 
responses as anti-inflammatory functions of HO-1 in non-eosinophilic asthma were associated with inhibition 
of Th17 responses55.
Several therapeutic strategies including injection of tolerogenic cells, recombinant proteins, monoclonal anti-
bodies to inflammatory cytokines, pharmacological agents and oral tolerance have been explored in EAE56,57. 
However, long-term safety issues and particularly in pregnant and lactating women are of major concern with 
currently used therapies for MS58. Promising clinical results in relapsing-remitting multiple sclerosis prompted 
dissection of cellular and molecular mechanisms of action of IVIG in EAE58. We have recently reported that 
IVIG inhibits both Th1 and Th17 responses in EAE model41 and similar to HO-1 induction model of Chora 
et al.23, significantly inhibited CNS infiltration of T cells. Confirming the in vitro results, the protection rendered 
by IVIG in EAE was not associated with HO-1 induction. It was however not surprising given that endogenous 
expression of HO-1 had no consequence on EAE and daily injection of CoPP was required to induce HO-1 in 
mice and to protect from EAE23. Current data show that without activating HO-1, therapeutic benefits could be 
obtained in EAE. Thus, our results exemplify the multi-faceted mechanisms of IVIG to exert anti-inflammatory 
Figure 4. The protective effect of IVIG in EAE is independent of induction of HO-1 in vivo. (a) Treatment of 
mice (n = 10) with IVIG significantly delays the onset of EAE and the severity of the disease in C57BL/6J mice. 
Control mice (n = 10) received 0.2 M glycine while IVIG group received 0.8 g/kg IVIG daily from day 0 to 19. 
Mean clinical scores (± SEM) are presented. ***p < 0.001, two-way ANOVA with Bonferroni post-t-test. 
(b) Expression of HO-1 in kidney and liver of IVIG-treated EAE mice. The mice treated with CoPP were used 
as a positive control. Images have been cropped for presentation.
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effects independent of HO-1 pathway. These results could be further consolidated by using HO-1-deficient mice. 
However, data from such mice would be difficult to interpret due to complex interactions of the HO-1 pathway 
products with various immune and non-immune cells.
IVIG products are not uniform and display variations with respect to formulation, stabilizing agents and 
source of plasma of healthy donors. Although these variations could influence the outcome of therapy of pri-
mary immunodeficiency patients, all IVIG products appear to have similar therapeutic benefits in autoimmune 
patients. Of note, when different IVIG preparations were examined for their effect on DC activation, endothelial 
functions, and Th17 differentiation and expansion, all tested IVIG preparations exerted similar effects37,59. In this 
report, we found that lack of induction of HO-1 by IVIG is not restricted to particular innate cell or IVIG prepa-
ration. In addition to Gamunex® , other three IVIG preparations (Sandoglobulin® , Tegeline® and Gammagard® ) 
were also inefficient to induce HO-1. Thus, our data indicate that inability of IVIG to induce HO-1 is a universal 
phenomenon irrespective of preparations.
Methods
Human Cell culture. Buffy coats from the healthy donors were purchased from Centre Necker-Cabanel, 
Etablissement Français du Sang (EFS), Paris, France. Ethical committee permission was obtained for the use 
of buffy bags of healthy donors (Institut National de la Santé et de la Recherche-EFS ethical committee permis-
sion N°12/EFS/079) and experiments were performed in accordance with the approved guidelines of INSERM. 
Peripheral blood mononuclear cells (PBMCs) were purified from the buffy coats by density gradient centrifuga-
tion using Ficoll-paque PREMIUM (GE healthcare, France). CD14+ monocytes were isolated from PBMCs by 
positive selection with CD14 microbeads (Miltenyi Biotec, France). They were cultured for 6 days in RPMI-1640 
medium plus 10% fetal calf serum containing GM-CSF (1000 IU/million cells) and IL-4 (500 IU/million cells) to 
obtain monocyte-derived DCs60.
Murine macrophages. All animal studies were approved and performed according to the guidelines of 
Charles Darwin ethical committee for animal experimentation (Université Pierre et Marie Curie Paris) at the 
pathogen-free animal facility of Centre de Researche des Cordeliers, Paris. Murine peritoneal macrophages were 
extracted from C57BL/6J mice (purchased from Janvier Laboratories, France) by intraperitoneal lavage and cul-
tured in Dubelcco’s Modified Eagle’s Medium supplemented with 1% penicillin, 1% streptomycin, 5% amino acids 
and 5% fetal bovine serum.
Murine RAW264.7 macrophages were maintained in Dubelcco’s Modified Eagle’s Medium supplemented with 
1% penicillin, 1% streptomycin, 5% amino acids and 5% fetal bovine serum.
All cells were maintained at 37 °C in humidified air containing 5% CO2.
Preparations of IVIG. Gamunex® (Grifols Bioscience, USA) was used throughout the study. In addition, 
Gammagard® , Sandoglobulin® , and Tegeline® were also used for in vitro experiments. They were dialysed against 
a large volume of PBS followed by RPMI-1640 medium at 4 °C for 18 hours to remove the stabilizing agents. IVIG 
was used at concentrations of 5, 10 or 15 mg/ml/0.5 million cells.
Animals and EAE. All animal studies were approved and performed according to the guidelines of 
Charles Darwin ethical committee for animal experimentation (Université Pierre et Marie Curie Paris) at the 
pathogen-free animal facility of Centre de Researche des Cordeliers, Paris.
Ten-week old C57BL/6J mice (purchased from Janvier Laboratories, France) were injected intraperitoneal 
with CoPP 20 mg/kg. After 24 hours, liver and kidney were recovered and snap-frozen for western-blot analysis 
to check the HO-1 expression.
To induce EAE, C57BL/6J mice (10/group) were immunized with 200 μ g MOG35–55 peptide emulsified in 
complete Freund’s adjuvant (1:1 by volume containing 800 μ g of nonviable desiccated Mycobacterium tuberculosis 
H37Rv. In addition, 300 ng of pertussis toxin was given intravenously on the same day and 2 days later. Clinical 
signs of EAE were assessed daily based on the following scoring system: 0, no signs; 1, tail paresis; 2, hind limb 
paresis; 3, hind limb paralysis; 4, tetraplegia; and 5, moribund. From the day of the immunization until the peak 
of the disease (day 19), mice received daily intraperitoneal injections of 16 mg (0.8 g/kg) IVIG (Gamunex® ). The 
control groups received equal volumes of 0.2 M glycine, the excipient of Gamunex® ).
Detection of HO-1 by Western blot. Human monocytes, DCs and RAW264.7 macrophages (0.5 million 
cells per ml) were treated with different IVIG preparations and with CoPP 25 μ M, the activator of HO-1. After 
24 hours, supernatants were removed and cells were lysed with a lysis buffer (20 mM dithiothreitol, 6% SDS, 
0.25 M Tris, 10% glycerol and 10 mM Na Fluoride, pH = 6.8). In another set of experiments, following 24 hours 
treatment of monocytes with IVIG, LPS (10 ng/ml; Sigma-Aldrich, France) was added to the cells to stimulate 
the monocytes and to induce inflammatory cytokines. After 24 hours, supernatants were removed and cells were 
lysed.
Liver and kidneys from EAE mice at the peak of the disease (day 19 following induction of EAE) or from the 
mice injected with CoPP were lysed with the lysis buffer.
Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing con-
ditions and transferred to polyvinylidene fluoride membrane. HO-1 was detected using an anti-HO-1 rat mon-
oclonal IgG (R&D Systems, France), a horseradish peroxidase-conjugated rabbit anti-rat IgG, and the enhanced 
chemiluminescence kit. β -actin was detected with a mouse anti-β -actin antibody (Sigma-Aldrich).
Phenotype analysis of monocytes treated with IVIG. Peripheral blood monocytes from the healthy 
donors were stimulated with LPS for 30 min. They were then exposed to IVIG for 48 hours. The expression of 
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CD80 and CD86 was analyzed by flow cytometry using PE-conjugated MAbs to CD80 and FITC-conjugated 
MAbs to CD86 (both from BD Biosciencies).
Cytokine analysis. IL-6 in the cell-free culture supernatants was quantified by ELISA (Ready-SET-Go, eBi-
oscience, France). The detection limit was 2 pg/ml.
Measurement of NO production. Peritoneal macrophages from C57Bl/6J mice and RAW264.7 cells were 
treated with IVIG (10 mg/ml) for 24 hours. They were then exposed to either LPS alone or LPS and SnMP (25 μ M; 
Frontier Scientific, USA) for additional 24 hours. Production of NO was evaluated by Griess method.
Statistical analysis. Two-way analysis of variance (ANOVA) with Bonferroni’s post-test was used to ana-
lyze daily clinical score. One-way ANOVA was used to determine the statistical significance of the in vitro data. 
P value of less than 0.05 was considered significant.
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